AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04659070
Drug: Experimental : Ezetimibe / Rosuvastatin + Telmisartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks
Trial: NCT04659070
Drug: Active comparator1 : Ezetimibe / Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks
Trial: NCT01113346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For children aged less than 1 y.o.: Placebo, 1/2 tablet 2 times a day for 7 days.~For children aged 1-4 y.o.: Placebo, 1 tablet 2 times a day for 7 days.
Trial: NCT02081495
Drug: DOXIL/CAELYX reference product (Treatment A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive DOXIL/CAELYX reference product 50 mg/m2 as an intravenous (into a vein) infusion over 90 minutes on Day 1.
Trial: NCT02081495
Drug: DOXIL/CAELYX test product (Treatment B)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive DOXIL/CAELYX test product 50 mg/m2 as an intravenous infusion over 90 minutes on Day 1.
Trial: NCT01595360
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is applied directly to the bleeding site after tooth extraction
Trial: NCT02896127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
Trial: NCT01587742
Drug: CCB use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of CCB during the study period between January 1, 1996 to December 31, 2009. The CCBs administered to the patients include isradipine and lacidipine.
Trial: NCT00552110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to MFNS given every morning and every evening x 2 weeks.
Trial: NCT01628926
Drug: SPM 962
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Trial: NCT02549027
Drug: MK-6096
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral MK-6096 tablets (5 mg strength)
Trial: NCT02549027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
Trial: NCT01628926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPM962-placebo patch and Ropinirole-placebo tab
Trial: NCT00003141
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02700451
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Age 18-64: Intravenous Ketorolac 30 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.~Age 65-75: Intravenous Ketorolac 15 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
Trial: NCT02700451
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Acetaminophen 1000mg every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
Trial: NCT02700451
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Normal Saline every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
Trial: NCT02652624
Drug: E/C/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/10 mg FDC tablet administered orally once daily with food
Trial: NCT02652624
Drug: E/C/F/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/300 mg FDC administered orally once daily with food
Trial: NCT02652624
Drug: RTV
RxNorm normalized name: Accu-Chek SmartView Test Strips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTV 100 mg tablets administered orally once daily with food
Trial: NCT02652624
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200/300 mg tablet administered orally once daily with food
Trial: NCT02652624
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/200/25 mg FDC tablet administered orally once daily without regard to food
Trial: NCT01672957
Drug: Immunosuppressive Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol does not specify any particular immunosuppressive drug and regimen for treatment. The choice of immunosuppressive therapy will be made prior to enrollment by the treating physician.
Trial: NCT00714779
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-40 mg / day orally
Trial: NCT01766375
Drug: Cyclosporin A,mycophenolate mofetil,Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration.
Trial: NCT04554433
Drug: Ethanol with Asprin
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group ( A ) which will receive the new protocol will be categorized into sub-groups according to the medical conditions , inclusion criteria , investigations and symptoms .~1. Inhaling alcohol vapor through nostrils .~2. Inhalation of Alcohol vapor driven by Oxygen .~3. Inhalation of Alcohol vapor driven by oxygen in case of ARDS.~4. Ethyl Alcohol infusion into the airway . Investigations will be made before starting the protocol and follow up data will be collected every day .~Follow up test will be done according to the schedule . PCR test will be done according to the duration of each technique to evaluate the final results .
Trial: NCT02103478
Drug: ASTX727 Dose Confirmation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization cross over design for courses 1 and 2
Trial: NCT02103478
Drug: ASTX727 Fixed-Dose Combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose investigational product
Trial: NCT00666367
Drug: D-cure
RxNorm normalized name: Cocci-Cure C for Calves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of D-cure (SMB oral intake) in syringe Exacta-Med Oral Dispenser.
Trial: NCT00666367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of Arachidis oleum raffinatum Ph. Eur. in syringe Med Oral Dispenser.
Trial: NCT02357576
Drug: Intralipid 20% I.V. Fat Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01014507
Drug: 8 cycles BEACOPPesc plus oral contraceptive
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03101709
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
Trial: NCT00902356
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
Trial: NCT00691236
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4mg IV 3 weekly for 6 doses
Trial: NCT00691236
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adriamycin + Cisplatinum and Ifosfamide
Trial: NCT03304379
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasinumab-matching placebo (solution for injection in pre-filled syringe); NSAID-matching placebo (capsule)
Trial: NCT00617240
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500/0mg tablets, 250-2000mg/day divided BID to TID, po, 26 weeks
Trial: NCT02003625
Drug: meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02003625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01140425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution once daily x 7 days
Trial: NCT01087424
Drug: R mini CHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 40 mg/m2 D1 D2 D3 D4 D5 Rituximab 375 mg/m2 D1 Doxorubicine 25 mg/m2 D1 Cyclophosphamide 400 mg/m2 D1 Vincristine 1 mg/m2 D1
Trial: NCT02271945
Drug: MEDI-551 12 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13
Trial: NCT02455076
Drug: Rapid-acting insulin analogs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If the BG levels are \>140 mg/dL, rapid acting insulin analogs will be administered following the supplemental/sliding scale protocol. If a patient is able and expected to eat all or most of his/her meals, supplemental insulin will be administered before each meal and at bedtime following the usual dose of the sliding scale protocol. If a patient is not able to eat, supplemental insulin will be administered every 6 hours following the sensitive dose of the sliding scale. If the BG is 141-180 mg/dL, then 2,3 or 4 units of insulin will be given; for BG 181 - 220 mg/dL; the units of insulin will be 3, 4 or 6; for BG 221 - 260 mg/dL, the units of insulin will be 4,5 or 8; for BG 261 - 300 mg/dL, the units of insulin will be 5, 6 or 10; for BG 301 - 350, the insulin will be 6, 8 or 12 units; for BG 351 - 400 mg/dL, the units of insulin will be 7,10 or 14; for BG\> 400 mg/dL, the insulin will be 8,12 or 16 units.
Trial: NCT00627679
Drug: MAP0010 intermediate dose
RxNorm normalized name: PREVOTELLA INTERMEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
Trial: NCT00409292
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally daily for as long as the participant continues to receive a benefit.
Trial: NCT01430065
Drug: ASP015K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01020019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control
Trial: NCT01918475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml of NaCl 0.9% is administered intravenously
Trial: NCT01121211
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone 300mcg transdermal patch x 24 weeks.
Trial: NCT01121211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo transdermal patch x 24 weeks
Trial: NCT03251248
Drug: MSB11455
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive MSB11455 either on Period 1 Day 1 or Period 2 Day 1.
Trial: NCT01557075
Drug: Pravastatin (High dose statin treatment)
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~Pravastatin 20mg daily for 12 months after randomization
Trial: NCT02867306
Drug: ASP1707
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02867306
Drug: methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT02597062
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04040192
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle ointment
Trial: NCT00576316
Drug: Symbicort Turbuhaler 160/4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01013558
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.15 microgram/kg/min continuous infusion.
Trial: NCT03016819
Drug: AL3818
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
Trial: NCT01930058
Drug: MK-8876
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.
Trial: NCT01971658
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01971658
Drug: Velcade®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01898793
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01328457
Drug: Paromomycin sulfate
RxNorm normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paromomycin IM Injection, 11 mg/kg as the base, intramuscular, once a day on 21 consecutive days (or no more than 22 days if one injection is missed during the treatment period).
Trial: NCT03196219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varnish Placebo
Trial: NCT01126580
Drug: LY2189265
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01126580
Drug: Placebo (oral)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01126580
Drug: Placebo (subcutaneous)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02770157
Drug: Genotropin®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00827892
Drug: Placebo Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose Capsule administered by mouth daily for the duration of the study as determined by MRI
Trial: NCT02485119
Drug: BAY94-9343
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: 4.5 mg/kg of BAY 94-9343 at Q3W dose regimen. Cohort 2: 6.5 mg/kg of BAY 94-9343 at Q3W dose regimen.
Trial: NCT01769157
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03860896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04527068
Drug: Tripleitriumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240mg intravenously every 3week
Trial: NCT01714466
Drug: NER1006
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00084695
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03992326
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Trial: NCT02929576
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02782897
Drug: Immunoglobulin Therapy
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin is given intravenously 0.4 g/kg per day for five consecutive days.
Trial: NCT00859755
Drug: ARRY-403, glucokinase activator; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, escalating
Trial: NCT00859755
Drug: Placebo; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT01815957
Drug: Rnalozine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: . After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.
Trial: NCT01636141
Drug: OLT1177 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee
Trial: NCT01636141
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00014534
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/ sq m IV
Trial: NCT00273364
Drug: Standard treatment with a conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)
Trial: NCT03154619
Drug: 0.1% TR 987
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TR 987 0.1%
Trial: NCT03154619
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel twice weekly for 4 weeks, then once weekly for 8 weeks. Gel will be applied to cover the wound cavity and wound surface to a thickness of 5 mm.
Trial: NCT02242877
Drug: Telmisartan combined with hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / telmisartan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01837316
Drug: FF/VI 100/25 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First strip: Fluticasone furoate inhalation powder blended with lactose, 100 mcg per blister
Trial: NCT01837316
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First strip: Inhalation powder of lactose
Trial: NCT02320019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching YH14618
Trial: NCT02320019
Drug: YH14618
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01157481
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy
Trial: NCT02692157
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Neurokinin 1,3 antagonist
Trial: NCT00989729
Drug: Physiological Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
Trial: NCT03218722
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg Saline solution.
Trial: NCT00910715
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxycycline 100 mg bid, 10 days
Trial: NCT00910715
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxycycline 100 mg bid, 15 days
Trial: NCT00910715
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control subjects without a history of Lyme borreliosis
Trial: NCT00073905
Drug: capecitabine plus gemcitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine plus gemcitabine
Trial: NCT01824303
Drug: LiRIS 400 mg
RxNorm normalized name: IRIS TENAX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LiRIS 400 mg contains lidocaine which is gradually released into the bladder over 14 days.
Trial: NCT02267655
Drug: inhaled Nitric Oxide - 30 mcg/kg IBW/hr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled Nitric Oxide in 30 mcg/kg IBW/hr doses Part 1
Trial: NCT02267655
Drug: inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr dose titration
Trial: NCT02267655
Drug: inhaled nitric oxide 75 mcg/kg IBW/hr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled nitric oxide 75 mcg/kg IBW/hr -Part 2b
Trial: NCT01513291
Drug: MK-6096
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-6096, two 5 mg tablets (total 10 mg dose), orally, once daily
Trial: NCT01513291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2 tablets, orally, once daily
Trial: NCT03127124
Drug: NANT-008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel: benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI)
Trial: NCT03127124
Drug: Fluorouracil Injectable Product
RxNorm normalized name: fluorouracil Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione.
Trial: NCT03127124
Drug: Avastin Injectable Product
RxNorm normalized name: Avastin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant humanized monoclonal IgG1 antibody
Trial: NCT03127124
Drug: Leucovorin Calcium Injection
RxNorm normalized name: Leucovorin Calcium Injection
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Calcium N -\[p -\[\[\[(6RS )-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1).